A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects with Chronic Hepatitis C Previously Treated with an NS5A Inhibitor + Sofosbuvir Therapy Save

Date Added
June 27th, 2017
PRO Number
Pro00067786
Researcher
Ira Willner

Silhouette
Keywords
Liver
Summary

The study will enroll well-compensated cirrhotic as well as non-cirrhotic Genotype 1 HCV infected subjects who are treatment experienced with Sovaldi (Sofosbuvir) and an NS5a Inhibitor (such as Harvoni). Subjects will be randomized to 12 or 16 weeks of treatment of G/P with or without Ribavirin.

Institution
MUSC
Recruitment Contact
Francis Beylotte
843-876-4273
beylott@musc.edu

Change_preferences

-- OR --

Create_login